269 related articles for article (PubMed ID: 18973819)
1. Is urethane-chloralose anaesthesia appropriate for pharmacokinetic-pharmacodynamic assessment? Studies with carvedilol.
Bertera FM; Di Verniero CA; Mayer MA; Bramuglia GF; Taira CA; Höcht C
J Pharmacol Toxicol Methods; 2009; 59(1):13-20. PubMed ID: 18973819
[TBL] [Abstract][Full Text] [Related]
2. Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a N-nitro-l-arginine methyl ester rat model of secondary hypertension.
Di Verniero CA; Bertera F; Buontempo F; Bernabeu E; Chiappetta D; Mayer MA; Bramuglia GF; Taira CA; Höcht C
J Pharm Pharmacol; 2010 Jul; 62(7):890-900. PubMed ID: 20636877
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic properties of carvedilol in fructose hypertensive rats.
Bertera F; Di Verniero CA; Mayer MA; Chiappetta D; Buontempo F; Polizio AH; Taira CA; Höcht C
Xenobiotica; 2012 Feb; 42(2):206-19. PubMed ID: 21892881
[TBL] [Abstract][Full Text] [Related]
4. Enantioselective pharmacokinetics and cardiovascular effects of nebivolol in L-NAME hypertensive rats.
Bertera FM; Del Mauro JS; Lovera V; Chiappetta D; Polizio AH; Taira CA; Höcht C
Hypertens Res; 2014 Mar; 37(3):194-201. PubMed ID: 24132009
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
Beddies G; Fox PR; Papich MD; Kanikanti VR; Krebber R; Keene BW
Am J Vet Res; 2008 Dec; 69(12):1659-63. PubMed ID: 19046015
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic modeling of diltiazem in spontaneously hypertensive rats: a microdialysis study.
Bertera FM; Mayer MA; Opezzo JA; Taira CA; Bramuglia GF; Höcht C
J Pharmacol Toxicol Methods; 2007; 56(3):290-9. PubMed ID: 17560132
[TBL] [Abstract][Full Text] [Related]
7. Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic (PK-PD) modeling of carvedilol.
Liu XY; Wang BJ; Yuan GY; Guo RC
Yao Xue Xue Bao; 2009 Apr; 44(4):406-11. PubMed ID: 19545060
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs.
Arsenault WG; Boothe DM; Gordon SG; Miller MW; Chalkley JR; Petrikovics I
Am J Vet Res; 2005 Dec; 66(12):2172-6. PubMed ID: 16379664
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
[TBL] [Abstract][Full Text] [Related]
10. Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure.
Tenero DM; Henderson LS; Campanile AM; Baidoo CA; Boyle D
Am J Cardiol; 2006 Oct; 98(7A):27L-31L. PubMed ID: 17023229
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic/pharmacodynamic modeling of the cardiovascular effects of beta blockers in humans.
Baek IH; Yun MH; Yun HY; Kwon KI
Arch Pharm Res; 2008 Jun; 31(6):814-21. PubMed ID: 18563366
[TBL] [Abstract][Full Text] [Related]
12. Comparison of different pharmacodynamic models for PK-PD modeling of verapamil in renovascular hypertension.
Bertera FM; Mayer MA; Opezzo JA; Taira CA; Höcht C
J Pharmacol Toxicol Methods; 2008; 57(3):212-9. PubMed ID: 18442930
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study.
Höcht C; Di Verniero C; Opezzo JA; Bramuglia GF; Taira CA
Naunyn Schmiedebergs Arch Pharmacol; 2006 Jul; 373(4):310-8. PubMed ID: 16733693
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic properties of a new controlled-release formulation of carvedilol.
Tenero DM; Henderson LS; Baidoo CA; Harter AH; Campanile AM; Danoff TM; Boyle D
Am J Cardiol; 2006 Oct; 98(7A):5L-16L. PubMed ID: 17023227
[TBL] [Abstract][Full Text] [Related]
15. Applicability of microdialysis as a technique for pharmacokinetic-pharmacodynamic (PK-PD) modeling of antihypertensive beta-blockers.
Höcht C; DiVerniero C; Opezzo JA; Taira CA
J Pharmacol Toxicol Methods; 2005; 52(2):244-50. PubMed ID: 16125622
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of the effects of nitric oxide synthase and cyclo-oxygenase inhibition on duodenal functions in rats anaesthetized with inactin, urethane or alpha-chloralose.
Sababi M; Nylander O
Acta Physiol Scand; 1996 Sep; 158(1):45-52. PubMed ID: 8876747
[TBL] [Abstract][Full Text] [Related]
17. Acute cardiovascular effects and pharmacokinetics of carvedilol in healthy dogs.
Sawangkoon S; Miyamoto M; Nakayama T; Hamlin RL
Am J Vet Res; 2000 Jan; 61(1):57-60. PubMed ID: 10630779
[TBL] [Abstract][Full Text] [Related]
18. Effects of cilostazol on the pharmacokinetics of carvedilol after oral and intravenous administration in rats.
Lim TH; Cho YA; Choi DH
J Physiol Pharmacol; 2015 Aug; 66(4):591-7. PubMed ID: 26348083
[TBL] [Abstract][Full Text] [Related]
19. Estimation of carvedilol in human plasma by using HPLC-fluorescence detector and its application to pharmacokinetic study.
Rathod R; Prasad LP; Rani S; Nivsarkar M; Padh H
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 857(2):219-23. PubMed ID: 17702675
[TBL] [Abstract][Full Text] [Related]
20. Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats.
Kim MS; Baek IH
Eur J Pharm Sci; 2018 Jan; 111():13-19. PubMed ID: 28942006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
